Form 4: Bolt Biotherapeutics Director, Brian O'Callaghan, Reports Stock Option Grant

Brian O'Callaghan, a director at Bolt Biotherapeutics, reported the acquisition of stock options for 22,000 shares on June 12, 2024.

Summary

• On June 14, 2024, a Form 4 filing was submitted to the SEC regarding Brian O'Callaghan's beneficial ownership of Bolt Biotherapeutics, Inc. securities.
• Brian O'Callaghan, a director of Bolt Biotherapeutics, acquired stock options for 22,000 shares of common stock on June 12, 2024.
• The exercise price of the stock options is $0.7682.
• The options vest on the earlier of June 12, 2025, or the day before the next annual meeting of stockholders, contingent upon continuous service.
• The options will fully vest upon a change in control of the Issuer.
• The options expire on June 11, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is neither particularly positive nor negative on its own.

Positives

• The acquisition of stock options by a director signals confidence in the company's future performance.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the stock option grant as an incentive for the director to work towards increasing shareholder value.

Key Dates